January 10, 2018 / 2:09 PM / 13 days ago

BRIEF-LIDDS Successfully Completes NanoZolid Study

Jan 10 (Reuters) - LIDDS AB:

* REG-LIDDS: NANOZOLID® WITH IMMUNE-STIMULATING AGENT CONFIRMS EFFICACY IN AN ADDITIONAL CANCER MODEL

* SAYS ‍CLEAR ANTI-TUMOR EFFECTS HAVE BEEN OBSERVED IN ANOTHER CANCER MODEL IN MICE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below